ABCA6
ABCa6: A Novel Biomarker for Early Detection and Monitoring of Alzheimer‘s Disease
Description
ABCa6 is an apolipoprotein (a protein that binds to lipids) that plays a crucial role in cholesterol homeostasis and cellular lipid metabolism. It is expressed primarily in the brain and liver and is involved in the transport of cholesterol from the central nervous system (CNS) to the liver for excretion.
In recent years, research has identified ABCa6 as a potential biomarker for Alzheimer‘s disease (AD). Studies have shown that ABCa6 levels are decreased in the cerebrospinal fluid (CSF) and brain tissue of AD patients. This decrease is thought to be associated with the accumulation of amyloid-beta plaques, a hallmark of AD pathology.
Associated Diseases
Alzheimer‘s Disease (AD)
AD is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and changes in behavior. It is the most common form of dementia, affecting millions of people worldwide. ABCa6 levels have been found to be significantly decreased in individuals with AD, and this decrease has been shown to correlate with disease severity.
Did you Know ?
- A study published in the journal "Neurology" found that individuals with the lowest levels of ABCa6 in their CSF were 3.5 times more likely to develop AD over a 4-year period.
